Oncology Pipeline

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.

PD-1 Inhibitor

Sintilimab, LY3342901

Image under development

The interaction of programmed cell death protein 1 (PD-1) transmembrane protein receptor, which is found in lymphocytes and monocytes, with its natural ligands programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2), is one of the major pathways exploited by cancer cells for immune evasion.1-3 The PD-1/ligand interactions strongly counteract T-cell antigen receptor (TCR) signal transduction and subsequently attenuate cytokine production, T-cell survival, and proliferation.4
Sintilimab (LY3342901) is a recombinant, fully human anti–PD-1 monoclonal antibody that has been shown in preclinical studies to bind to PD-1 and block interactions between PD-1 and PD-L1/PD-L2 to restore antitumor immunity.5 Sintilimab enhances T-cell function, including antitumor responses, through blockade of PD-1 binding to PD-L1 and PD-L2, which are expressed in antigen presenting cells.5,6
Clinical Development
Sintilimab is being investigated in a clinical trial in patients with non-small cell lung cancer.


  1. Agata Y, et al. Int Immunol. 1996;8(5):765-772.
  2. Ishida Y, et al. EMBO J. 1992;11(11):3887-3895.
  3. Marin-Acevedo JA, et al. J Hematol Oncol. 2018;11(1):39.
  4. Chen L, Flies DB. Nat Rev Immunol. 2013;13(4):227-242.
  5. Wang J, et al. MAbs. 2019;11(8):1443-1451.
  6. Zhang S, et al. Antib Ther. 2018;1:65-73.

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.


IDH1 Inhibitor

Learn More

RET Inhibitor

Learn More

KRAS G12C Inhibitor

Learn More